Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
( DrugBank: Dextromethorphan, Dextromethorphan hydrobromide, Quinidine, Quinidine sulfate / KEGG DRUG: Dextromethorphan hydrobromide, Dextromethorphan, Dextromethorphan polistirex, Dextromethorphan hydrobromide, Dextromethorphan, Dextromethorphan polistirex, Quinidine gluconate, Quinidine polygalacturonate, Quinidine sulfate, Quinidine, Quinidine gluconate, Quinidine polygalacturonate, Quinidine sulfate, Quinidine )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 867 / Drugs : 820 - (DrugBank : 185) / Drug target genes : 189 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|